Seminars in Nephrology
Volume 31, Issue 6 , Pages 483-494, November 2011

Update in Diuretic Therapy: Clinical Pharmacology

  • D. Craig Brater, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to D. Craig Brater, Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine Fairbanks Hall, 340 West 10th St, Suite 6200, Indianapolis, IN 46202

Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN

Summary 

All diuretics except spironolactone exert their effects from the lumen of the nephron. Thus, to exert an effect, they must reach the urine. Pharmacokinetics (PK) describes this access. Different edematous disorders can affect access to this site of action and therein affect response to a diuretic. In addition, once a diuretic reaches the site of action, a response ensues. The characteristics of this response that can be affected by a patient's clinical condition are described by the pharmacodynamics (PD) of a diuretic. To understand the mechanisms of abnormal response to a diuretic one must dissect its PK and PD in different edematous disorders. For example, in patients with renal insufficiency, the mechanism of poor diuretic response is PK. In contrast, in patients with cirrhosis or in those with congestive heart failure, it is PD. In patients with nephrotic syndrome, both PK and PD are operative. These different mechanisms mandate differences in therapeutic strategy, as explained in this article.

Keywords: Diuretic, edema, renal insufficiency, nephrotic syndrome, cirrhosis, congestive heart failure

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the General Clinical Research Center (MO1 RR00750) and R01 DK 37994 and R01 AG 07631.

PII: S0270-9295(11)00132-X

doi:10.1016/j.semnephrol.2011.09.003

Seminars in Nephrology
Volume 31, Issue 6 , Pages 483-494, November 2011